A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib.
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 19 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.